Navigation
Home
Advocating for Access
Background
Letters for Access
Press Releases For Access
Simplified Community Materials
Simplified Community Materials
Understanding your HCV infection
Community Led Reports
Country Information
Indonesia
India
Vietnam
Generic DAAs Pricing
Resources
Guidelines
Key Research Publication
Other Important Documents and Reports
News
Gallery
Photos
Video
Stories
Response from CEO, CHAI about the Quick Start program in November 2016
Response from CEO, CHAI about the Quick Start program in November 2016
Please click here
December 21, 2016
/
News
Share
the Post
Related
Posts
Pricing of Indian generic sofosbuvir, 30th Jan,2016
New WHO guideline on care and treatment of chronic hepatitis C
Patient Groups and CSOs in Asia written a letter to Indian Government to Request Waiver on Local Clinical Trial for The Coming Generic DAAs
Part 2: How is hepatitis C treated?
Patent Situation of The Key Product for Treatment of Hepatitis C: DACLASTAVIR – WHO working paper, revised version, Oct 2014
Read More
Story from Ajitshwor Wangkheirakpam, Manipur, India
Patent Situation of The Key Product For Treatment of Hepatitis C: SOFOSBUVIR – WHO working paper, updated 2015
Part 1: What is hepatitis C and how is it diagnosed?
